Home / Tag Archives: GLP-1 receptor agonists (page 10)

Tag Archives: GLP-1 receptor agonists

Type 2 Diabetes Drug Sequencing: A Step-by-Step Treatment Guide

Close-up of type 2 diabetes treatment planning with medication bottles, glucose-lowering drugs, and a clinical flowchart for drug sequencing

Treating type 2 diabetes is no longer a one-size-fits-all endeavor. As new therapies emerge, clinicians face the ongoing challenge of selecting and sequencing medications in a way that balances efficacy, safety, cost, and patient preference. This comprehensive guide to type 2 diabetes drug sequencing outlines practical strategies for initiating, intensifying, …

Read More »

Beyond GLP‑1s: Are We Overlooking the Role of SGLT2 Inhibitors and Metformin?

Assorted diabetes medications including metformin and SGLT2 inhibitors arranged on a wooden surface beside a white pill bottle.

Clinicians and care teams are increasingly focused on GLP‑1 receptor agonists, but SGLT2 inhibitors and metformin in diabetes management remain foundational in achieving comprehensive, evidence‑based outcomes. While GLP‑1 therapies generate headlines for weight loss and glucose control, 2025 guidelines still strongly emphasize the cardioprotective and renoprotective benefits of SGLT2 inhibitors …

Read More »

GLP‑1s Beyond Weight Loss: Are We Overlooking Neuroprotective Benefits?

Illustration of a middle-aged man with a visible brain overlay and insulin pen, symbolizing GLP-1 neuroprotective effects on cognition in diabetes.

The class of medications known as GLP-1 receptor agonists — commonly prescribed for type 2 diabetes and increasingly used for weight loss — may offer more than just metabolic benefits. Growing evidence indicates that GLP-1 drugs could play a role in protecting the brain. Could this mean a dual benefit …

Read More »